Development of the myocite biobank: Cost-efficient model of public sector investigator-driven biobank for idiopathic inflammatory myositis

Background: Biobanking refers to the cryopreservation of the various biologic samples for future research. In the era of omics, biobanking has emerged as a vital process to aid research, more so for rare diseases. Aims and Methods: We describe herein the development of a biobank for idiopathic infl...

Full description

Saved in:
Bibliographic Details
Main Authors: R Naveen, Anamika Kumari Anuja, Mohit Kumar Rai, Vikas Agarwal, Latika Gupta
Format: Article
Language:English
Published: SAGE Publishing 2020-01-01
Series:Indian Journal of Rheumatology
Subjects:
Online Access:http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=6;spage=194;epage=199;aulast=Naveen
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832568799701762048
author R Naveen
Anamika Kumari Anuja
Mohit Kumar Rai
Vikas Agarwal
Latika Gupta
author_facet R Naveen
Anamika Kumari Anuja
Mohit Kumar Rai
Vikas Agarwal
Latika Gupta
author_sort R Naveen
collection DOAJ
description Background: Biobanking refers to the cryopreservation of the various biologic samples for future research. In the era of omics, biobanking has emerged as a vital process to aid research, more so for rare diseases. Aims and Methods: We describe herein the development of a biobank for idiopathic inflammatory myopathies (IIMs), a rheumatic illness with low prevalence. This study addresses the sample collection, transport, storage, maintenance, retrieval, and disposal of samples with a focus on cost-effectiveness, limitations, ethics, and legal aspects involved. Discussion: Financial constraints are juxtaposed next to a wealth of clinical data in the developing countries with a large population size and consequently high burden of rare diseases. Fine-tuning efforts toward the development of bio-archival facilities can maximize outcomes from research units in these countries. A time and cost-efficient model can be the first step toward such initiatives in the appropriate setting. Unique ethical, executive, and scientific challenges were encountered by the authors while establishing the MyoCite biobank in a resource-poor setting. The various efforts to foreclose these obstacles are discussed. Conclusion: This brief summarizes the unmet need, unique challenges, and potential solutions based on the authors' experiences gathered while setting up the MyoCite biobank for research in IIM. It also outlines the means and directions for national and global collaborations in the times ahead.
format Article
id doaj-art-b5eb6e58dfe14401a09f1ef00dc9b888
institution Kabale University
issn 0973-3698
0973-3701
language English
publishDate 2020-01-01
publisher SAGE Publishing
record_format Article
series Indian Journal of Rheumatology
spelling doaj-art-b5eb6e58dfe14401a09f1ef00dc9b8882025-02-03T00:25:16ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012020-01-0115619419910.4103/injr.injr_95_20Development of the myocite biobank: Cost-efficient model of public sector investigator-driven biobank for idiopathic inflammatory myositisR NaveenAnamika Kumari AnujaMohit Kumar RaiVikas AgarwalLatika GuptaBackground: Biobanking refers to the cryopreservation of the various biologic samples for future research. In the era of omics, biobanking has emerged as a vital process to aid research, more so for rare diseases. Aims and Methods: We describe herein the development of a biobank for idiopathic inflammatory myopathies (IIMs), a rheumatic illness with low prevalence. This study addresses the sample collection, transport, storage, maintenance, retrieval, and disposal of samples with a focus on cost-effectiveness, limitations, ethics, and legal aspects involved. Discussion: Financial constraints are juxtaposed next to a wealth of clinical data in the developing countries with a large population size and consequently high burden of rare diseases. Fine-tuning efforts toward the development of bio-archival facilities can maximize outcomes from research units in these countries. A time and cost-efficient model can be the first step toward such initiatives in the appropriate setting. Unique ethical, executive, and scientific challenges were encountered by the authors while establishing the MyoCite biobank in a resource-poor setting. The various efforts to foreclose these obstacles are discussed. Conclusion: This brief summarizes the unmet need, unique challenges, and potential solutions based on the authors' experiences gathered while setting up the MyoCite biobank for research in IIM. It also outlines the means and directions for national and global collaborations in the times ahead.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=6;spage=194;epage=199;aulast=Naveenbiobankdermatomyositisethicsindiamusclemyositispolymyositisurine
spellingShingle R Naveen
Anamika Kumari Anuja
Mohit Kumar Rai
Vikas Agarwal
Latika Gupta
Development of the myocite biobank: Cost-efficient model of public sector investigator-driven biobank for idiopathic inflammatory myositis
Indian Journal of Rheumatology
biobank
dermatomyositis
ethics
india
muscle
myositis
polymyositis
urine
title Development of the myocite biobank: Cost-efficient model of public sector investigator-driven biobank for idiopathic inflammatory myositis
title_full Development of the myocite biobank: Cost-efficient model of public sector investigator-driven biobank for idiopathic inflammatory myositis
title_fullStr Development of the myocite biobank: Cost-efficient model of public sector investigator-driven biobank for idiopathic inflammatory myositis
title_full_unstemmed Development of the myocite biobank: Cost-efficient model of public sector investigator-driven biobank for idiopathic inflammatory myositis
title_short Development of the myocite biobank: Cost-efficient model of public sector investigator-driven biobank for idiopathic inflammatory myositis
title_sort development of the myocite biobank cost efficient model of public sector investigator driven biobank for idiopathic inflammatory myositis
topic biobank
dermatomyositis
ethics
india
muscle
myositis
polymyositis
urine
url http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=6;spage=194;epage=199;aulast=Naveen
work_keys_str_mv AT rnaveen developmentofthemyocitebiobankcostefficientmodelofpublicsectorinvestigatordrivenbiobankforidiopathicinflammatorymyositis
AT anamikakumarianuja developmentofthemyocitebiobankcostefficientmodelofpublicsectorinvestigatordrivenbiobankforidiopathicinflammatorymyositis
AT mohitkumarrai developmentofthemyocitebiobankcostefficientmodelofpublicsectorinvestigatordrivenbiobankforidiopathicinflammatorymyositis
AT vikasagarwal developmentofthemyocitebiobankcostefficientmodelofpublicsectorinvestigatordrivenbiobankforidiopathicinflammatorymyositis
AT latikagupta developmentofthemyocitebiobankcostefficientmodelofpublicsectorinvestigatordrivenbiobankforidiopathicinflammatorymyositis